DeepCyte launched with $1.5 million in seed funding to commercialize single-cell drug toxicity prediction tools. The company said its MetaCore platform pairs laser-based single-cell sampling with mass spectrometry to create atlas-scale, AI-ready metabolomics datasets aimed at modeling heterogeneous drug responses. DeepCyte also released DeeImmuno, an AI software product that predicts drug toxicity classes, identifies biomarkers, and infers toxicity mechanisms using machine learning trained on its proprietary single-cell metabolomics atlases. The company cited evaluation across 100 drugs with reported accuracy for predicting multiple toxicity mechanisms. By targeting toxicity prediction earlier and at single-cell resolution, DeepCyte is positioning itself as an enabling technology for discovery and translational teams looking to prioritize safety risk reduction before late-stage programs.